Paper Details

  1. Home
  2. Paper Details

Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.

Author: BossHildegard, CastroHenry, EmotteCorinne, GolorGeorge, HorsmansYves, LiudmilaMateva, PrestonRichard A, QuinlanMichelle, SellamiDalila, ShiboletOren, ZhouJocelyn

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study assessed the pharmacokinetics (PKs) and safety of sonidegib, a Hedgehog signaling pathway inhibitor, in subjects with varying degrees of hepatic impairment. The study aims to provide dose recommendations for patients with hepatic impairment based on PKs and safety data.
Paper Details　
Original Abstract of the Article :
Sonidegib is a potent, selective and orally bioavailable inhibitor of the Hedgehog signaling pathway, primarily metabolized by the liver. In order to make dose recommendations for patients with hepatic impairment, we have assessed here the pharmacokinetics (PKs) and safety of sonidegib in subjects w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40262-017-0560-2

データ提供：米国国立医学図書館（NLM）

Sonidegib and Liver Function: A Balancing Act

Sonidegib is a promising drug for treating certain types of cancer, but its effectiveness can be affected by liver function. This study explores the pharmacokinetic profile of sonidegib in patients with varying degrees of hepatic impairment. The authors conducted a multicenter study to evaluate the safety and effectiveness of sonidegib in individuals with impaired liver function, providing valuable insights for dose adjustments and treatment strategies.

Optimizing Sonidegib Dosing: A Personalized Approach

The study's findings highlight the importance of considering individual liver function when prescribing sonidegib. The researchers identified significant differences in sonidegib pharmacokinetics among patients with varying degrees of hepatic impairment, suggesting the need for dose adjustments to ensure optimal therapeutic efficacy while minimizing potential adverse effects. This research provides valuable guidance for clinicians to personalize sonidegib dosing based on individual patient characteristics.

Liver Health and Cancer Treatment: A Complex Relationship

The liver plays a crucial role in drug metabolism, and its function can impact the efficacy and safety of cancer treatments. This study underscores the importance of monitoring liver function in patients receiving sonidegib, particularly those with pre-existing liver conditions. By carefully managing liver health, clinicians can optimize treatment outcomes and minimize potential complications.

Dr.Camel's Conclusion

Navigating the complex terrain of cancer treatment often involves balancing the effectiveness of therapies with the potential for side effects. This study, like a camel navigating the desert, provides valuable insights into the delicate relationship between sonidegib and liver function. It reminds us that a personalized approach, considering individual patient needs, is essential for maximizing treatment benefits while minimizing risks.

Date :
  1. Date Completed 2019-06-10
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

28577129

DOI: Digital Object Identifier

10.1007/s40262-017-0560-2

Related Literature

Article Analysis
・Effects of sonidegib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.